
The combination produced a 36.7% confirmed response rate and median progression-free survival of 6.9 months in an early Phase 2 study.
BioNTech and Bristol Myers Squibb said their experimental drug pumitamig, combined with docetaxel, showed a 36.7% confirmed response rate in a Phase 2 trial of advanced non-small cell lung cancer. Median progression-free survival was 6.9 months among the 50 patients treated.
The ROSETTA Lung-107 study enrolled patients whose cancer had progressed during or after first-line immunotherapy plus chemotherapy. At the July 10, 2026 data cut-off, 33 patients remained on treatment, and 30 could be assessed for response. Median follow-up was 12.2 weeks.
The companies reported responses across squamous and non-squamous cancer types and across PD-L1 expression levels. The disease control rate was 90% among evaluable patients. The study is testing pumitamig at 1,400 milligrams with docetaxel every three weeks.
The companies described the safety profile as manageable, with no new safety signals. Pumitamig-related adverse events led to treatment discontinuation in four patients, or 8% of the 50-person safety group.
The data were presented at the 2026 European Society for Medical Oncology Congress. BioNTech and Bristol Myers said the findings support further study of pumitamig in this patient group, where they described treatment needs as high.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.